William Bowen, MD
Cardiovascular Disease · Saint Louis, MONPI 1609815950
Payments from drug & device makers
Across 166 payments — averaging $4373.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$724K
- AbbVie$441
- AstraZeneca$254
- Novo Nordisk$229
- Pfizer$206
- Lilly USA, LLC$167
- plus $805 from 14 others
Across 3 payments — averaging $234,006 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$702K
- Eli Lilly$21
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 25 | $723,814 |
| AbbVie(2 entities) | 24 | $441 |
| AstraZeneca | 20 | $254 |
| Novo Nordisk | 17 | $229 |
| Pfizer | 17 | $206 |
| Lilly USA, LLC | 13 | $167 |
| Amgen | 6 | $109 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Amarin Pharma, Inc. | 5 | $74 |
| Johnson & Johnson | 4 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
| Novartis | 5 | $65 |
| GSK | 5 | $59 |
| Arbor Pharmaceuticals, Inc. | 4 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Shire North American Group Inc | 2 | $32 |
| Recor Medical Inc | 1 | $23 |
| Welch Allyn | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$725,918 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Saint Louis
- Mohammad TahirSaint Louis$2.7M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- Mustafa HusainiSaint Louis$465K
- Denise JanosikSaint Louis$295K
- Farhan KatchiSaint Louis$245K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.